Boehringer Ingelheim’s survodutide shows promise in liver fibrosis treatment
Phase 2 trial reveals significant improvement in MASH patients
Read More
Tag: liver
Resolution unveils data for liver disease treatment at EASL 2024
Extended phase 2 study highlights macrophage cell therapy’s efficacy
Read More
Silent plight
Why a new approach is needed for primary biliary cholangitis trials
Read More
CymaBay begins phase 3 liver disease study
IDEAL study aims to determine the impact of seladelpar on alkaline phosphatase levels
Read More
Gilead to reveal pivotal liver disease research
Gilead will present real-world data on its efforts to advance WHO’s aim of eliminating viral hepatitis
Read More
Novartis and Pfizer link to develop NASH combo therapy
Novartis and Pfizer have announced an agreement that aims to advance the treatment of non-alcoholic steatohepatitis (NASH), a form of liver disease.
Read More
Gilead presents promising data for NASH drug
Gilead has presented promising Phase II results for its experimental NASH drug GS-0976, showing significant reductions in the build up of liver fat and a marker of fibrosis.
Read More
US fast track for Shire’s liver drug
US regulators have placed Shire’s SHP626 on a fast-track regulatory pathway in the hope of potentially accelerating access to the experimental liver disease drug.
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
